Venous thromboembolism (VTE) is a common complication among patients with cancer.
The 6-month risk of VTE complication for cancer patients is 12-fold higher and as
much as 23-fold higher in those receiving chemotherapy or targeted therapy when compared
to patients without cancer [
[1]
]. Furthermore, the 12-month cumulative incidence for VTE has increased three-fold
over the past two decades in this patient population [
[1]
]. Hence, cancer-associated thrombosis (CAT) is a frequent complication that most clinicians
caring for patients with cancer must routinely manage.Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Venous thromboembolism in cancer patients: a population-based cohort study.Blood. 2021; 137: 1959-1969
- Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.J Thromb Haemost. 2007; 5: 632-634
- What impact does venous thromboembolism and bleeding have on cancer patients' quality of life?.Value Health. 2018; 21: 449-455
- Experience of living with cancer-associated thrombosis in spain (PELICANOS).Support Care Cancer. 2018; 26: 3233-3239
- Patients' experiences of living with cancer-associated thrombosis: the PELICAN study.Patient Prefer Adherence. 2015; 9: 337-345
- Patient experience of living with cancer-associated thrombosis in Canada (PELICANADA).Res Pract Thromb Haemost. 2020; 4: 154-160
- Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.Blood. 2002; 100: 3484-3488
- Prognosis of cancers associated with venous thromboembolism.N Engl J Med. 2000; 343: 1846-1850
- Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update.J Clin Oncol. 2020; 38: 496-520
- American society of hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.Blood Adv. 2021; 5: 927-974
- SEOM clinical guideline of venous thromboembolism (VTE) and cancer.Clin Transl Oncol. 2019; 22 (2020): 171-186
- Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence.Eur J Intern Med. 2022; 100: 36-48https://doi.org/10.1016/j.ejim.2022.02.020
- GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines.BMJ. 2016; 353: i2089
- GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: introduction.BMJ. 2016; 353: i2016
- GRADE guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health.J Clin Epidemiol. 2016; 76: 89-98
Article info
Publication history
Published online: March 28, 2022
Accepted:
March 24,
2022
Received:
March 22,
2022
Identification
Copyright
© 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidenceEuropean Journal of Internal MedicineVol. 100
- PreviewVenous thromboembolism (VTE) is a leading cause of morbidity and mortality among cancer patients. They develop more VTE than those without cancer and experience higher rates of VTE recurrence and haemorrhagic complications [1] that vary depending on patient-related risk factors, tumour site, cancer stage, and anticancer treatments [2].
- Full-Text
- Preview
